Overview

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

Status:
RECRUITING

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3K) inhibitor, as a single agent and in combination with either sotorasib or trametinib in participants with advanced solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

Vividion Therapeutics, Inc.

Treatments:

sotorasib
trametinib